The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway

Cancer spectrum and frequency among children with Noonan, Costello and cardio-facio-cutaneous syndromes

(2015) C P Kratz et al.   BRITISH JOURNAL OF CANCER

K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling

(2015) Man-Tzu Wang et al.   CELL

KRAS as a Therapeutic Target

(2015) F. McCormick   CLINICAL CANCER RESEARCH

Behavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1

(2015) Thijs van der Vaart et al.   NEUROLOGY

PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation

(2014) Kim M. Keppler-Noreuil et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Cardiovascular disease in Noonan syndrome

(2014) T. W. Prendiville et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas

(2014) B. C. Widemann et al.   NEURO-ONCOLOGY

The RASopathies

(2013) Katherine A. Rauen   Annual Review of Genomics and Human Genetics

Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma

(2013) Geoffrey T. Gibney et al.   Nature Reviews Clinical Oncology

Achieving consensus for clinical trials: The REiNS International Collaboration

(2013) S. R. Plotkin et al.   NEUROLOGY

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors

(2012) Walter J. Jessen et al.   JOURNAL OF CLINICAL INVESTIGATION